311 related articles for article (PubMed ID: 29385676)
1. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.
Hernandez B; Adissu HA; Wei BR; Michael HT; Merlino G; Simpson RM
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385676
[TBL] [Abstract][Full Text] [Related]
2. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma.
Simpson RM; Bastian BC; Michael HT; Webster JD; Prasad ML; Conway CM; Prieto VM; Gary JM; Goldschmidt MH; Esplin DG; Smedley RC; Piris A; Meuten DJ; Kiupel M; Lee CC; Ward JM; Dwyer JE; Davis BJ; Anver MR; Molinolo AA; Hoover SB; Rodriguez-Canales J; Hewitt SM
Pigment Cell Melanoma Res; 2014 Jan; 27(1):37-47. PubMed ID: 24128326
[TBL] [Abstract][Full Text] [Related]
3. Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison.
Prouteau A; André C
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31262050
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas.
Gillard M; Cadieu E; De Brito C; Abadie J; Vergier B; Devauchelle P; Degorce F; Dréano S; Primot A; Dorso L; Lagadic M; Galibert F; Hédan B; Galibert MD; André C
Pigment Cell Melanoma Res; 2014 Jan; 27(1):90-102. PubMed ID: 24112648
[TBL] [Abstract][Full Text] [Related]
5. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
6. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.
Segaoula Z; Primot A; Lepretre F; Hedan B; Bouchaert E; Minier K; Marescaux L; Serres F; Galiègue-Zouitina S; André C; Quesnel B; Thuru X; Tierny D
BMC Cancer; 2018 Dec; 18(1):1219. PubMed ID: 30514258
[TBL] [Abstract][Full Text] [Related]
8. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
10. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
Acosta AM; Kadkol SS
Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
[TBL] [Abstract][Full Text] [Related]
12. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Hendricks WPD; Zismann V; Sivaprakasam K; Legendre C; Poorman K; Tembe W; Perdigones N; Kiefer J; Liang W; DeLuca V; Stark M; Ruhe A; Froman R; Duesbery NS; Washington M; Aldrich J; Neff MW; Huentelman MJ; Hayward N; Brown K; Thamm D; Post G; Khanna C; Davis B; Breen M; Sekulic A; Trent JM
PLoS Genet; 2018 Sep; 14(9):e1007589. PubMed ID: 30188888
[TBL] [Abstract][Full Text] [Related]
13. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
14. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
15. IQGAP1 is an oncogenic target in canine melanoma.
Lee BH; Neela PH; Kent MS; Zehnder AM
PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
[TBL] [Abstract][Full Text] [Related]
16. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.
Wong K; van der Weyden L; Schott CR; Foote A; Constantino-Casas F; Smith S; Dobson JM; Murchison EP; Wu H; Yeh I; Fullen DR; Joseph N; Bastian BC; Patel RM; Martincorena I; Robles-Espinoza CD; Iyer V; Kuijjer ML; Arends MJ; Brenn T; Harms PW; Wood GA; Adams DJ
Nat Commun; 2019 Jan; 10(1):353. PubMed ID: 30664638
[TBL] [Abstract][Full Text] [Related]
17. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
18. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.
Fowles JS; Denton CL; Gustafson DL
Vet Comp Oncol; 2015 Sep; 13(3):288-304. PubMed ID: 23745794
[TBL] [Abstract][Full Text] [Related]
20. Atypical
Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
